IL-6 Blockade with Clazakizumab is Associated with Low Myeloid Cell Activation and Increased Type 2 Immune Responses in Non-survivors of COVID-19.
BACKGROUND IL-6 inhibitors have been associated with reduced mortality in severe COVID-19 in randomized clinical trials, but the comprehensive immunological impact of IL-6 blockade in the setting of an acute viral infection is poorly understood. METHODS To gain insight into the systemic immune response to IL-6 inhibi...